Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs: a population record-linkage study in Tayside, Scotland

TY - JOUR

T1 - Prevalence estimates of diagnosed viral hepatitis B, liver condition outcomes and hospitalization costs

T2 - a population record-linkage study in Tayside, Scotland

AU - McLernon, D.J.

AU - Donnan, P.T.

AU - Dillon, J.F.

PY - 2013

Y1 - 2013

N2 - We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62% vs. 48%), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24% of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.

AB - We estimated prevalence and incidence of liver condition outcomes, and costs to the health service of diagnosed hepatitis B virus (HBV) in Tayside, UK. HBV patients were identified from electronic virology data between 1989 and 2003. The health resource costs of HBV for surface antigen-positive (HBsAg+) patients and HBV (HBsAg+ or immune, i.e. recovered) patients were calculated. A total of 633 patients had HBV (275 HBsAg+), and were more likely to be male (62% vs. 48%), older (mean age 42·6 vs. 39·2 years) and deprived than the general population. The prevalence of immune individuals increased steadily. Post-HBV diagnosis, 24% of immune and 13% of HBsAg+ patients were diagnosed with a liver condition. The median cost per immune patient (£3023) was greater than per HBsAg+ patient (£1498) (P = 0·02). While increasing prevalence of immune HBV patients highlights an increase in screening and treatment, the costs associated with this group are high.

KW - Hepatitis B.

KW - EPIDEMIOLOGY

KW - DISEASE

KW - BURDEN

KW - VIRUS

UR - https://www.scopus.com/pages/publications/84883367182

U2 - 10.1017/S095026881200266X

DO - 10.1017/S095026881200266X

M3 - Article

C2 - 23200407

AN - SCOPUS:84883367182

SN - 0950-2688

VL - 141

SP - 2122

EP - 2130

JO - Epidemiology and Infection

JF - Epidemiology and Infection

IS - 10

ER -